NCT06236269View on ClinicalTrials.gov

HR+/HER2- Advanced or Metastatic Breast Cancer Patients Treated With Sacituzumab Govitecan

PHASE2RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

March 15, 2024

Primary Completion Date

February 20, 2026

Study Completion Date

February 20, 2027

Conditions
Breast Cancer Stage IV
Interventions
DRUG

Sacituzumab Govitecan

Sacituzumab Govitecan 10 mg/kg will be administrad intravenously (IV) on Days 1, 8 of a 21-day cycle

Trial Locations (10)

18016

NOT_YET_RECRUITING

HU Clínico San Cecilio, Granada

28040

NOT_YET_RECRUITING

Fundación Jiménez Díaz, Madrid

28041

NOT_YET_RECRUITING

Hospital Universitario 12 de Octubre, Madrid

41013

NOT_YET_RECRUITING

Hospital Universitario Virgen del Rocio, Seville

43204

RECRUITING

Hospital Sant Joan de Reus, Reus

46010

NOT_YET_RECRUITING

Hospital Clínico de Valencia, Valencia

08916

NOT_YET_RECRUITING

ICO Badalona, Badalona

08907

NOT_YET_RECRUITING

ICO Hospitalet, L'Hospitalet de Llobregat

08035

NOT_YET_RECRUITING

Hospital Universitari Vall d'Hebrón, Barcelona

08036

RECRUITING

Hospital Clínic de Barcelona, Barcelona

All Listed Sponsors
lead

SOLTI Breast Cancer Research Group

OTHER